Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

ziprasidone (GEODON, ZELDOX)


DRUG AND DIETARY SUPPLEMENT PROFILES

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include Drug and Dietary Supplement Profiles where your selected drug is a secondary subject of discussion.


WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion.

Quetiapine (SEROQUEL) Drug Interactions and Heart Trouble
December 2011
Find out about 12 drugs that can interact with widely prescribed quetiapine -- 12 million prescriptions sold in 2010 -- to cause serious, sometimes fatal, heart arrhythmias.
Inappropriate Prescribing of Atypical Antipsychotic Drugs in the Elderly: Inexcusable Deaths and Medicare Dollars Wasted
August 2011
Most prescriptions for antipsychotic drugs to people in nursing homes are inappropriate and quite dangerous. Find out what you can do to protect your family or friends.
Dangers of Mixing Alcohol with Certain Medications or Diseases
August 2008
The article discusses 273 drugs that can have harmful interactions with alcohol. Also reviewed are several ways in which these harmful interactions can occur: 1/ Medications Can Increase Alcohol Blood Levels 2/ Additive effects of medications and alcohol. One of the best- known drug-alcohol interactions is when alcohol, a depressant, is taken with other sedative medications, and excessive sedation or depression of respiration can occur 3/Alcohol can increase the blood levels of some medications leading to toxicity of these drugs. 4/ Alcohol also can reduce blood levels of some medications causing them to be less effective. Although some of the interactions between alcohol and medications mainly occur in people who drink heavily (three or more drinks on one occasion), many of these interactions may occur with much lower amounts of alcohol use, such as one to two drinks on an occasion. We strongly urge you to tell your physicians and other health care providers how much alcohol you are drinking so they can effectively assess the risks and advise you about the safe use of alcohol and medications.
A Review of Ranolazine (RANEXA) For Chronic Chest Pain
March 2007
Although the FDA medical officer in charge of reviewing ranolazine recommended that ranolazine's professional product labeling display a black box warning about potential disruption in the heart's electrical cycle, the drug does not have a black box warning.
Do Not Use Until December 2009 The New Antipsychotic Drug Aripiprazole (ABILIFY)
June 2003
You should follow the Health Research Group’s Seven Year Rule with aripiprazole. There is no evidence to suggest that aripiprazole is a “breakthrough” drug.
New Research Results on Safety of Newly Approved Drugs Causes Health Research Group to Extend Five-Year Waiting Rule to Seven Years
June 2002
A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group’s drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug’s professional product labeling or its outright removal from the market. You should wait at least seven years from the date of release to take any new drug unless it is one of those rare “therapeutic advances” that offers you a documented therapeutic advantage over older, proven drugs.
Outrage: New Study: Wait Seven Years to Use New Drugs
June 2002
A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market. Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion.

Letter to FDA Opposing Approval of Loxapine Inhalation Powder (Adasuve) (HRG Publication #1997)
Public Citizen’s Health Research Group strongly opposes FDA approval of loxapine (Adasuve) inhalation powder for treatment of schizophrenia or bipolar I disorder in adults due to no evidence from clinical trials that it offers any benefits over currently-available treatments and that it can cause life-threatening pulmonary toxicity.
FDA Should Give Oral Presentations at All Advisory Committee Meetings, Public Citizen Tells Agency
Agency experts should be required to give presentations at all future Food and Drug Administration (FDA) advisory committee meetings discussing specific products, Public Citizen said in a petition filed today.
Statement at FDA Hearing on Risk Management of Prescription Drugs (HRG Publication #1620)
The single most important risk management strategy the FDA can undertake in the short-term to reduce the publics risk from preventable adverse drug reactions is to go forward as rapidly as possible with regulations that require pharmacists to distribute scientifically accurate, useful written drug information, or Medication Guides, approved by the agency. At the very least, this would provide consumers with a reliable source of information that they can use to protect themselves from preventable injury.